BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 530 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fithian, LLC | 101,020 | $7,494,674 | 15.66% |
| Montanaro Asset Management Ltd | 387,800 | $28,770,882 | 4.47% |
| Brown Capital Management | 3,262,377 | $242,035,750 | 3.62% |
| Sandhill Capital Partners LLC | 501,059 | $37,173,549 | 3.56% |
| STONE RUN CAPITAL, LLC | 89,435 | $6,635,183 | 3.17% |
| DF DENT & CO INC | 2,949,044 | $218,789,610 | 3.08% |
| Ownership Capital B.V. | 2,324,358 | $172,444,120 | 3.03% |
| Jackson Square Partners, LLC | 1,485,067 | $110,177,121 | 2.98% |
| Summit Creek Advisors LLC | 283,412 | $21,026,336 | 2.74% |
| Spence Asset Management | 111,666 | $8,284,501 | 2.65% |
| MAIRS & POWER INC | 3,025,978 | $224,497,293 | 2.59% |
| Pembroke Management, LTD | 305,005 | $22,628,321 | 2.47% |
| AMERICAN CAPITAL MANAGEMENT INC | 886,827 | $65,793,695 | 2.32% |
| Aristotle Atlantic Partners, LLC | 523,186 | $38,815,170 | 2.00% |
| Handelsinvest Investeringsforvaltning | 148,000 | $10,980 | 1.75% |
| GENEVA CAPITAL MANAGEMENT LLC | 1,070,257 | $79,402,344 | 1.62% |
| Select Equity Group, L.P. | 5,640,897 | $418,498,148 | 1.49% |
| Eversept Partners, LP | 188,659 | $13,996,611 | 1.22% |
| BAMCO INC /NY/ | 5,379,492 | $399,104,511 | 1.20% |
| Dorsey & Whitney Trust CO LLC | 142,838 | $10,597,152 | 0.96% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q1 2023. To view BIO-TECHNE CORP's shareholder history, click here.